Aeglea BioTherapeutics, Inc. (AGLE) has 26 open-market insider trades by 13 insiders since 2016. The most active filer is Anthony G. Quinn, CEO & President.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Eli & Co Lilly | 10% Owner | — | 1 | $5.0M | 2016-04-12 |
| Ag Novartis | 10% Owner | — | 2 | $3.8M | 2018-05-08 |
| Anthony G. Quinn | CEOPres | — | 10 | $3.0M | 2022-03-16 |
| Novartis Bioventures Ltd | 10% Owner | — | 2 | $1.7M | 2018-05-11 |
| Armen Shanafelt | Dir | — | 1 | $1.1M | 2021-12-13 |
| Jonathan Alspaugh | CFO | — | 3 | $667K | 2022-03-11 |
| Orbimed Advisors LLC | 10% Owner | — | 1 | $564K | 2017-02-21 |
| Charles N. York II | CFO | — | 1 | $116K | 2017-12-05 |
| Marcio Souza | Dir | — | 1 | $101K | 2022-08-25 |
| Anthony Quinn | Dir | — | 1 | $100K | 2016-04-12 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Marcio Souza | Director | Buy | $101K | 2022-08-25 |
| Michael Conick Hanley Jr. | Chief Commercial Officer | Buy | $20K | 2022-06-08 |
| Anthony G. Quinn | CEO & President | Buy | $375K | 2022-03-16 |
| Anthony G. Quinn | CEO & President | Buy | $562K | 2022-03-11 |
| Jonathan Alspaugh | CFO | Buy | $156K | 2022-03-11 |
| Jonathan Alspaugh | CFO | Buy | $186K |
Companies that share insiders with AGLE, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| 2021-12-09 |
| Anthony G. Quinn | CEO & President | Buy | $358K | 2021-12-09 |
| Armen Shanafelt | Director | Buy | $1.1M | 2021-12-09 |
| Jonathan Alspaugh | CFO | Buy | $325K | 2021-08-16 |
| Anthony G. Quinn | CEO & President | Buy | $784K | 2020-04-30 |
| Anthony G. Quinn | CEO & President | Buy | $360K | 2019-06-12 |
| Anthony G. Quinn | CEO & President | Buy | $334K | 2019-05-20 |
| Anthony G. Quinn | President | Buy | $126K | 2019-02-15 |
| Aaron Schuchart | — | Sell | $57K | 2018-09-27 |
| Novartis Bioventures Ltd | 10% Owner | Sell | $197K | 2018-05-11 |